Gene Therapy Hits a Peculiar Roadblock: A Virus Shortage

November 28, 2017

(New York Times) – Eager to speed development of revolutionary treatments, the Food and Drug Administration recently announced that it would expedite approval of experimental gene therapies. But the regulatory process may not be the biggest obstacle here. Biotech companies have exciting plans to introduce treatments that may be transformative, sometimes curing genetic diseases with a single treatment. And the firms are itching to test their products. But they are struggling to obtain a critical component of the therapy: the disabled viruses used to slip good genes into cells that lack them.

Recommended Reading